Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 16/20 | 0.69 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23166440 | 1.00 | BCL2 (0.69) | BCL2BCL2L1 | |
| SCHEMBL30106002 | 0.94 | BCL2 (0.70) | BCL2BCL2L1 | |
| SCHEMBL21751782 | 0.94 | BCL2 (0.70) | BCL2BCL2L1 | |
| SCHEMBL23166122 | 0.93 | BCL2 (0.70) | BCL2BCL2L1 | |
| SCHEMBL23166129 | 0.93 | BCL2 (0.70) | BCL2BCL2L1 | |
| Hydrochloric Acid SCHEMBL21751676 | 0.93 | BCL2 (0.67) | BCL2BCL2L1 | |
| Hydrochloric Acid SCHEMBL30075029 | 0.93 | BCL2 (0.67) | BCL2BCL2L1 | |
| SCHEMBL23165822 | 0.92 | BCL2 (0.66) | BCL2BCL2L1 | |
| SCHEMBL23165824 | 0.92 | BCL2 (0.66) | BCL2BCL2L1 | |
| SCHEMBL23165551 | 0.92 | BCL2 (0.67) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | BCL2 2/4885BCL2L1 4/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | BCL2 2/4885BCL2L1 4/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | BCL2 3/4885BCL2L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.